TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05257993
Drug: JPI-547
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~* The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~* Capsules should be swallowed whole and should not be chewed, crushed or split.
Study: NCT05257993
Drug: modified FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: * After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~* After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~* Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~* Repeated administration every 2 weeks on a 14-day cycle
Study: NCT06247787
Drug: Hydrocortisone Sodium Succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive IT
Study: NCT06247787
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive IV or PO
Study: NCT06247787
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive IT
Study: NCT06137183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vixarelimab matching placebo will be administered as per the schedule specified in the respective arms.
Study: NCT05971173
Drug: Juven
Normalized name: Juven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements
Study: NCT06562608
Drug: Anticholinergic Deprescription
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: per routine clinical care, people in the active arm of the study will undergo deprescription of benztropine or trihexyphenidyl per routine clinical care.
Study: NCT06562608
Drug: No Anticholinergic Deprescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm, no deprescription of benztropine or trihexyphenidyl will occur.
Study: NCT05015439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study intervention will be supplied as a softgel capsule containing inert filler.
Study: NCT03816488
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salsalate 1.5 g administered 2 h before surgery
Study: NCT05231044
Drug: KX01 ointment 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental drug, KX01 Ointment 1% is used in participants with Clinically typical AK on the face or scalp.
Study: NCT05231044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ointment is used in participants with Clinically typical AK on the face or scalp.
Study: NCT05537948
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of PCSK9 inhibitors:The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with a PCSK9 inhibitor, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). Pitavastatin will initially be prescribed at a dose of 2 mg, after 1 month. in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg. There will be visits on the 7th, 9th and 12th months.
Study: NCT05325645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets will be orally administered once weekly for 7weeks.
Study: NCT04806503
Drug: UNR844
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution for topical ocular administration
Study: NCT04806503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05661409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be used as placebo. The inclusion of a placebo group would allow us to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
Study: NCT04299464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral placebo for approximately 12 weeks.
Study: NCT04299464
Drug: RO7017773
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral RO7017773 for approximately 12 weeks.
Study: NCT05159284
Drug: Hydrocortisone Ophthalmic
Normalized name: hydrocortisone ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop, for a total of 14 days of treatment. Repeat on day 28: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop. Patients in the intervention arm will receive two 14-day cycles of hydrocortisone.
Study: NCT05605509
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan Leucovorin FU
Study: NCT06011772
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06011772
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04903223
Drug: Rosuvastatin 10mg
Normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin will be administered to all participants on Study Day #2
Study: NCT05702177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single-dose of placebo matching daridorexant will be administered in the evening 30 minutes prior to bedtime.
Study: NCT06564545
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study: NCT05268510
Drug: CapOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles
Study: NCT05764525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 0 mg of VVZ-149
Study: NCT05955924
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nicotinamide (500 mg) twice daily
Study: NCT05955924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule twice daily
Study: NCT04345718
Drug: Treatment as Usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.
Study: NCT05100654
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
Study: NCT06451757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 100 mg placebo twice daily during 52 weeks
Study: NCT05514938
Drug: Usual Care (individual medications prescribed by primary cardiologist)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical prescriptions for post-acute coronary syndrome care including statin, aspirin, and prasugrel or clopidogrel.
Study: NCT05400109
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The mechanism of action is thought to involve cross-linking of tumor cell DNA
Study: NCT06180759
Drug: Intravenous infusion of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Placebo (saline infusion) will be administered.
Study: NCT04990830
Drug: Inhaled Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application with Soft Mist Inhaler
Study: NCT05919264
Drug: FOG-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days
Study: NCT05919264
Drug: mFOLFOX-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX-6 will be administered per the prescribing information in combination with FOG-001
Study: NCT05919264
Drug: Trifluridine/tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil will be administered per the prescribing information in combination with FOG-001
Study: NCT06406114
Drug: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous and intradermal skin testing will be performed in all participants. Concentrations for percutaneous testing; cefazolin (330 mg/ml), cefuroxime (90 mg/ml), ceftazidime (100 mg/ml), ceftriaxone (100 mg/ml), cefepime (200 mg/ml), pre-pen (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (6 mg/ml). Concentrations for the first intradermal testing; cefazolin (3.3mg/ml), cefuroxime (1 mg/ml), ceftazidime (1 mg/ml), ceftriaxone (1 mg/ml), cefepime (2 mg/ml), Pre-PEN (undiluted), penicillin G (1000 U/ml), ampicillin (20 mg/ml), and histamine (0.1 mg/ml). Concentrations for the second intradermal testing; cefazolin (33mg/ml), cefuroxime (10 mg/ml), ceftazidime (10 mg/ml), ceftriaxone (10 mg/ml), cefepime (20 mg/ml), Pre-PEN (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (0.1 mg/ml). Histamine and saline will be used as positive and negative controls.
Study: NCT04715529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo oral capsules (matching FZJ-003) in a dose escalation format .
Study: NCT05525286
Drug: SOT102
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOT102 is an antibody-drug conjugate (ADC) targeting CLDN18.2 with the anthracycline PNU as cytotoxic moiety.
Study: NCT05690711
Drug: HRS8179
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS8179 injection
Study: NCT05690711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological saline
Study: NCT06505187
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg every 12 hours
Study: NCT06505187
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 12 hours
Study: NCT04857957
Drug: Oral dose CNTX-6016 or oral dose Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTX-6016 or Placebo
Study: NCT05378906
Drug: DRV/COBI FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of DRV/COBI FDC tablet dispersed in water as per assigned treatment sequence.
Study: NCT05378906
Drug: DRV
Normalized name: Urinal Male Drv RTLPC23201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of DRV suspension as per the assigned treatment sequence.
Study: NCT06151964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching administration volumes for SC injection
Study: NCT00826046
Drug: Prochymal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
Study: NCT05636176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziltivekimab placebo s.c. injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
Study: NCT05322577
Drug: CAPOX
Normalized name: Capecitabine and Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOX administered as a combination of oxaliplatin as an IV infusion and capecitabine orally as tablets.
Study: NCT06242691
Drug: Antiemetic
Normalized name: ANTIEMETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or more prophylactic antiemetic(s) (e.g. 5-HT3 receptor antagonists, dexamethasone, neurokinin-1 receptor antagonists, etc.) may be selected based on previous response of participants to antiemetic medications and individual factors, and will be administered per approved product label prior to MK-1200 infusion
Study: NCT06419361
Drug: [68Ga]Ga-Sa-DABI-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.
Study: NCT06051227
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
Study: NCT05681780
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered on days -7 and -6.
Study: NCT06309992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching survodutide
Study: NCT05705518
Drug: Refresh Optive Mega-3 PF
Normalized name: CARBOXYMETHYLCELLULOSE SODIUM 5 mg in 1 mL / GLYCERIN 10 mg in 1 mL / POLYSORBATE 80 5 mg in 1 mL OPHTHALMIC SOLUTION/ DROPS [Refresh Optive Mega-3 PF]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product
Study: NCT05624554
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m\^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
Study: NCT05293171
Drug: 1.25 mg/kg BL-8040 + BL-8040-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous (SC) injection
Study: NCT05293171
Drug: 2 mg/kg BL-8040
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous (SC) injection
Study: NCT05293171
Drug: BL-8040-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneous (SC) injection
Study: NCT05753774
Drug: Conventional drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs include probiotics and omeprazole, and cyproheptadine and moxapride
Study: NCT05661903
Drug: Positron Emission Tomography / Magnetic Resonance Imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with imaging compatible devices will undergo positron emission tomography/magnetic resonance imaging at three time points during the study. This imaging involves administration of the \[11C\]PBR28 radioligand, which is an investigational drug. Only a subset of patients who have 3 Tesla magnetic resonance imaging compatible stimulators will undergo this imaging.
Study: NCT05900388
Drug: Standard of care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain. SOC including heparins, Vitamin K antagonists (VKAs) and Other Direct oral anticoagulants (DOACs).
Study: NCT06278350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group.
Study: NCT06415292
Drug: Winlevi (clascoterone) 1% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splitface design- Subjects applied Winlevi (clascoterone) cream 1%, twice daily to the randomized half face following cleansing, every morning and evening.
Study: NCT05783479
Drug: estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure
Study: NCT06339008
Drug: LY3650150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06339008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06339008
Drug: Standard therapy for INCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as intranasal spray
Study: NCT05741385
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine
Study: NCT06191042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection in the abdomen
Study: NCT05672576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
Study: NCT05219175
Drug: MDMA Assisted Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions with the first session using an initial dose of 100 mg MDMA HCL (\~80 mg MDMA) with supplemental dose of 40 mg MDMA HCL (\~35 mg MDMA). Total dose range for the first session is 100 mg MDMA HCL (\~80 mg MDMA) to 140 mg MDMA HCL (\~115 mg MDMA).The second and third sessions may use an initial dose of 120 mg MDMA HCL (\~100 mg MDMA) with a supplemental dose of 60 mg MDMA HCL (\~50 mg MDMA) for a total dose range of 120 mg MDMA HCL (\~100 mg MDMA) to 180 mg MDMA HCL (\~160 mg MDMA)~Total cumulative dose range for the three sessions is 340mg MDMA HCL (\~280 mg MDMA) to 500 mg MDMA HCL (\~435 mg MDMA)
Study: NCT04848064
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04105270
Drug: Oral Restorative Microbiota Therapy (RMT) Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly
Study: NCT06769685
Drug: Basal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A was treated with basal therapy including drugs such as interleukin-11, Ricocin, and Epsilon, and was administered until the PLT was ≥75×109/L.
Study: NCT06769984
Drug: SCTT11
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTT11 dose 1, dose 2, dose 3, dose 4
Study: NCT06769984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose 1, dose 2, dose 3, dose 4
Study: NCT06765564
Drug: iPSC-MNP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using iPSC-MNP Cells for the Treatment of ALS Patients
Study: NCT06263478
Drug: INCA034176
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05365477
Drug: Empiric Therapy: Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug(s): indapamide 1.25mg and potassium citrate 15mEq daily.
Study: NCT05365477
Drug: Selective Therapy: Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug(s):~For calcium \>250mg male, \>200mg female: indapamide 1.25mg and potassium chloride 20mEq. At 1 month if persistent, then increase to indapamide 2.5mg and potassium chloride 20mEq. For citrate \<450mg male, \<550mg female: potassium citrate 15mEq BID. At 1 month if persistent, then increase to potassium citrate 30mEq BID. For pH\<5.8: potassium citrate 15mEq BID. At month if persistent, then increase to potassium citrate 30mEq BID. For uric acid \>800mg male, \>750mg female: allopurinol 300mg.~If both elevated calcium and low pH: indapamide 1.25mg and potassium citrate 15mEq BID If both elevated calcium and low citrate: indapamide 1.25mg and potassium citrate 15mEq BID
Study: NCT04712435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
Study: NCT04778397
Drug: Steroidal Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per institutional standard during consolidation.
Study: NCT04294641
Drug: Steroid pulse (prednisone)
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-2mg/kg/day allowed for clinical disease stabilization during first 4 weeks after starting Ibrutinib.
Study: NCT04294641
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treat or prevent bronchiolitis obliterans.
Study: NCT05623189
Drug: HTD1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTD1801,1250 mg, BID
Study: NCT05623189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, BID
Study: NCT06229366
Drug: [Ac-225]-PSMA-62 (OmHSPC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle for up to 2 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle, for a total of 2 cycles.
Study: NCT05870553
Drug: Cool prep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel Preparation
Study: NCT05009979
Drug: F18-FDG
Normalized name: fluorodeoxyglucose F18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within approximately 2 weeks of each 18F-DCFPyL PET/CT scan, participants will be scanned with a 18F-FDG PET/CT imaging at the NIH Clinical Center using standard procedures. The 18F-FDG PET/CT imaging performed will allow the localization of viable tumor sites and characterize their FDG metabolism for comparison with 18F-DCFPyL imaging. The 18F-FDG PET/CT imaging will consist of an 18F-FDG injection and PET/CT imaging performed approximately 1 hour post 18F-FDG injection. A corresponding low dose CT scan for attenuation correction and co-registration purposes will be performed prior to the PET image.